Ubiquilin-2, Developmental Studies Hybridoma Bank, PCRP-UBQLN2-1C7

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human Ubiquilin-2 and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 10 commercial research antibodies against human Ubiquilin-2 encoded by UBQLN2.

The collection of antibodies was tested using HAP1 WT and UBQLN2 KO cells in the applications WB, IP and IF according to YCharOS standard protocols (see reference).

WB was performed using lysates (30 µg protein) from WT and KO cells. IP was performed using WT cell lysates, and immunoprecipitated fraction was analysed by WB using anti-Ubiquilin-2 85509 (1:1000) from Cell Signaling Technology. IF staining was performed using WT and KO cells.

WB with PDRP-UBQLN2-1C7 (antibody dilution 1:26) failed to produce any signal in lysates from HAP1 WT and KO cells.

Although the antigen was clearly detected in the starting material (4% of total material) and unbound (4% of total material) fractions, no corresponding band was observed in the immunoprecipitated fraction (2 µg antibody used).

In IF (1:20 antibody dilution), staining of comparable intensities was observed in WT and KO cells.

We highly encourage other scientists to share their observations.